The CoolXenon Study
| ISRCTN | ISRCTN75602528 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN75602528 |
| EudraCT/CTIS number | 2009-014260-19 |
| Secondary identifying numbers | Version 1.21 (as of 05/01/2011) |
- Submission date
- 26/11/2010
- Registration date
- 26/11/2010
- Last edited
- 19/02/2015
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Injury, Occupational Diseases, Poisoning
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Marianne Thoresen
Scientific
Scientific
School of Clinical Sciences
University of Bristol
Neonatology
St Michael's Hospital
Southwell Street
Bristol
BS2 8EG
United Kingdom
| Phone | +44 (0)117 342 5607 |
|---|---|
| Marianne.Thoresen@bristol.ac.uk |
Study information
| Study design | Interventional non-randomised single centre feasibility study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Non randomised controlled trial |
| Study setting(s) | GP practice |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | A feasibility study of adding xenon to cooling therapy in babies at high risk of brain injury following poor condition at birth |
| Study acronym | CoolXenon |
| Study objectives | Our experimental work has shown that by adding the inert gas xenon (50%) while undergoing hypothermia treatment the % good outcome doubles (from 35% to 70%) in both small and large survival models. This is the first clinical feasibility study combining xenon inhalation with the established neuroprotective hypothermia treatment in newborn term after moderate and severe perinatal asphyxia. Further reading: Dingley J, Tooley J. Porter H, Thoresen M. Xenon provides short term neuroprotection in neonatal rats when administered after hypoxia-ischemia. Stroke 2006; 37(2): 501-6. http://www.ncbi.nlm.nih.gov/pubmed/16373643 Dingley J, Hobbs C, Ferguson J, Thoresen M. Xenon/hypothermia neuroprotection regimes in spontaneously breathing neonatal rats after hypoxic-ischemic insult: respiratory and sedative effects. Anaesthesia and Analgesia 2008; 106: 916-923. http://www.ncbi.nlm.nih.gov/pubmed/18292440 Hobbs C, Thoresen M, Tucker AM, Aquilina K, Chakkarapani E, Dingley J. Xenon and hypothermia combine additively offering long term functional and histopathological neuroprotection after neonatal hypoxia-ischemia. Stroke 2008; 39(4): 1307-13. http://www.ncbi.nlm.nih.gov/pubmed/18309163 Chakkarapani E, Thoresen M, Hobbs C, Aquilina K, Liu X, Dingley J. A closed-circuit neonatal xenon delivery system: technical neuroprotection feasibility study in newborn pigs. Anaesthesia and Analgesia 2009; 109(2): 451-60. http://www.ncbi.nlm.nih.gov/pubmed/19608817 Thoresen M, Hobbs C, Wood T, Chakkarapani E, Dingley J. Cooling combined with immediate or delayed Xenon inhalation provides equivalent long-term neuroprotection after neonatal hypoxia-ischemia. Journal of Cerebral Blood Flow and Metabolism 2009; 29(4): 707-14. http://www.ncbi.nlm.nih.gov/pubmed/19142190 Thoresen M. Patient selection and prognostication with hypothermia treatment. Seminars in Fetal and Neonatal Medicine 2010; 15(5): 247-52 http://www.ncbi.nlm.nih.gov/pubmed/20580626 As of 01/03/2011 the target number of participants has been increased from 12 to 14 |
| Ethics approval(s) | North Somerset and South Bristol Research Ethics Committee approved on the 16th September 2009 (ref: 09/H0106/64) |
| Health condition(s) or problem(s) studied | Topic: Neurological; Subtopic: Neurological (all Subtopics); Disease: Nervous system disorders |
| Intervention | Adding xenon to the inspiratory gas of the ventilated infant using a MHRA approved closed loop xenon-delivery system. The xenon, oxygen, carbon dioxide (CO2) and nitrogen gas concentrations are controlled. Follow up length: 42 months Study entry: registration only Added 01/03/2011: The duration of treatment with Xenon gas has been increased from 12 hours to 18 hours for recruits 12, 13 and 14 |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Xenon |
| Primary outcome measure | Physiological changes, measured within 24 hours after end treatment |
| Secondary outcome measures | 1. Bayley III, measured at 18 or 24 months 2. MRI, measured within 14 days after treatment |
| Overall study start date | 28/03/2010 |
| Completion date | 01/03/2013 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | Added 01/03/2011: 14 (12 at time of registration) |
| Key inclusion criteria | Infants will be eligible for xenon if the St Michael's standard inclusion criteria for cooling are met. Standard Hypothermia Treatment Criteria for 72 hours of cooling - all of criteria A, B, and C: A: Infants greater than 36.0 weeks gestation (clinical assessment) with at least one of the following: 1. Apgar score of less than 5 at ten (10) minutes after birth 2. Continued need for resuscitation, including endotracheal or mask ventilation, at ten minutes after birth 3. Acidosis defined as either umbilical cord pH or any arterial, venous or capillary pH within 60 minutes of birth less than pH 7.00 4. Base deficit greater than or equal to 16 mmol/L in umbilical cord blood sample or any blood sample within 60 minutes of birth (arterial or venous blood) If the infant meets criterion A then assess for neurological abnormality using criterion B and C (by trained personnel). B: Moderate or severe encephalopathy as evidenced by: 1. Altered state of consciousness (reduced or absent responses or pathological irritability and hyper responsive And at least one or more of the following: 2. Hypotonia 3. Abnormal reflexes including oculomotor or pupillary abnormalities 4. Absent or weak suck 5. Clinical seizures, as recorded by trained personnel C: At least 30 minutes duration of amplitude integrated electroencephalography (aEEG) recording that shows abnormal background aEEG activity. The decision to cool is based on the worst section of the aEEG, not the best (al Naqeeb, et al, 1999) or seizures (clinical or electrical) thus meeting ONE of the following: 1. Normal background with some electrical seizure activity 2. Moderately abnormal activity (upper margin of trace greater than 10 µV and lower margin less than 5 µV) 3. Suppressed activity (upper margin of trace less than 10 µV and lower margin of trace less than 5 µV) 4. Definite seizure activity Additional inclusion criteria for xenon: Before being considered for additional inhaled xenon therapy via the breathing gas mixture, the infant would need to meet further additional entry criteria: 1. Intubated, ventilated, sedated, being cooled 2. Any seizures under control 3. Weight greater than 2.3 kg 4. No evidence of infection 5. Stable cardiovascular parameters - mean arterial pressure greater than 45mmHg 6. Oxygen requirement via mechanical ventilator less than 35% 7. Positive end expiratory pressure (PEEP) requirement less than 6 mmHg 8. Arterial pCO2 within the accepted range (4.5 - 6.5 kPa) 9. Postnatal age less than 18 hours, either sex 10. Major congenital abnormalities, imperforate anus and congenital abnormalities suggestive of chromosomal anomaly or other syndromes that include brain dysgenesis |
| Key exclusion criteria | 1. Infants expected to be greater than 12 hours of age at the time of starting cooling treatment 2. Futility; where prognosis is considered to be hopeless, e.g. no cardiac output for 20 minutes 3. Failure to meet the additional inclusion criteria for xenon |
| Date of first enrolment | 28/03/2010 |
| Date of final enrolment | 01/03/2013 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
School of Clinical Sciences
Bristol
BS2 8EG
United Kingdom
BS2 8EG
United Kingdom
Sponsor information
University Hospitals Bristol NHS Foundation Trust (UK)
Hospital/treatment centre
Hospital/treatment centre
Research and Development
Upper Maudlin Street
Bristol
BS2 8AE
England
United Kingdom
| Phone | +44 (0)117 342 0233 |
|---|---|
| research@uhbristol.nhs.uk | |
| Website | http://www.uhbristol.nhs.uk/ |
"ROR" |
https://ror.org/04nm1cv11 |
Funders
Funder type
Charity
Sparks (UK)
Private sector organisation / Other non-profit organizations
Private sector organisation / Other non-profit organizations
- Alternative name(s)
- Sparks Charity
- Location
- United Kingdom
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/05/2014 | Yes | No | |
| HRA research summary | 28/06/2023 | No | No |
